a*R*a*-2*9*0*: Innovative Peptide Therapy for Neuropathic Pain and Tissue Protection

• Customization: Available
• Application: Salon
• Disposable: Injection
• Model NO.: SD-G-B-2117
• Gender: Unisex
• Side Effect: Dry Mouth
• Usage: Injection
• Pharmaceutical Technology: Chemical Synthesis
• Efficacy: Weight Loss & Slimming
• Health Food Approval No.: Z02
• Transport Package: Lyophilized Powder in a Vial Customizable Versio
• Specification: 5mg/vial*10vials
• Trademark: Customizable
• Origin: Shandong, China
• HS Code: 30049090
• Production Capacity: 5000000 Pieces/Month

Product Description

Origin

A*R*A*-2*9*0 is a non-hematopoietic peptide derived from the tertiary structure of ery*thro*poie*tin (E*P*O). Specifically, it is modeled from the helix B domain of the E*P*O molecule. Unlike E*P*O, which stimulates red blood cell production and has been associated with serious side effects such as increased risk of thrombosis, A*R*A*-2*9*0 selectively interacts with the innate repair receptor (IRR) without causing ery*thro*poie*sis. This selective interaction allows A*R*A*-2*9*0 to mediate tissue protection and repair without the adverse effects linked to EPO.

Mechanism of Action

A*R*A*-2*9*0 exerts its therapeutic effects through several mechanisms. It primarily acts on the IRR to downregulate inflammatory pathways, thereby reducing inflammation. Additionally, A*R*A*-2*9*0 inhibits the activity of the TRPV1 channel, which is responsible for sensing heat and burning pain, commonly experienced in neuropathic conditions. This peptide also promotes nerve fiber regrowth from damaged axons, contributing to its neuroprotective properties. Furthermore, A*R*A*-2*9*0 inhibits macrophage activation and suppresses inflammatory cytokines such as IL-2, IL-6, and tumor necrosis factor, thus modulating the immune response and promoting tissue healing.

Clinical Applications

A*R*A*-2*9*0 has shown promise in a variety of clinical applications, particularly in the management of neuropathic pain and tissue protection. It has been evaluated in preclinical and clinical studies for conditions such as type 2 diabetes with neuropathy, diabetic retinopathy, myocardial infarction, chronic heart failure, burns, traumatic brain injury, and multi-organ failure. In a phase 2 clinical trial involving patients with type 2 diabetes and painful neuropathy, A*R*A*-2*9*0 demonstrated significant improvements in hemoglobin A1c (HbA1c) levels, lipid profiles, and neuropathic symptoms, as well as an increase in corneal nerve fiber density. These findings suggest that A*R*A*-2*9*0 may be beneficial for both metabolic control and neuropathy in patients with type 2 diabetes.

Dosage and Administration

The dosage of A*R*A*-2*9*0 can vary depending on the specific condition being treated. In clinical trials, a common regimen has been a daily subcutaneous injection of 4 mg for 28 days, followed by an additional month of observation without further treatment. The intranasal spray form of A*R*A*-2*9*0 is also available and is generally easier to administer. It is important to note that A*R*A*-2*9*0 should be used under the guidance of a healthcare professional, as the optimal dosage may need to be adjusted based on individual patient factors and response to treatment.

Storage

A*R*A*-2*9*0 should be stored according to the manufacturer's instructions to maintain its stability and efficacy. Typically, the peptide should be kept in a cool, dry place, protected from light and extreme temperatures. For example, the injectable form may require refrigeration, while the intranasal spray may have different storage requirements. Proper storage conditions are crucial to ensure the integrity of the product and its therapeutic effects.

Summary

A*R*A*-2*9*0 is a promising non-hematopoietic peptide derived from ery*thro*poie*tin, designed to selectively interact with the innate repair receptor. It offers significant therapeutic potential in the management of neuropathic pain and tissue protection, with demonstrated efficacy in preclinical and clinical studies. Its mechanism of action involves downregulation of inflammatory pathways, inhibition of pain-related channels, and promotion of nerve fiber regrowth. A*R*A*-2*9*0 is administered via subcutaneous injection or intranasal spray, with dosages tailored to individual patient needs. Proper storage conditions are essential to preserve its stability and effectiveness. As research and clinical trials continue, A*R*A*-2*9*0 holds the potential to become a valuable treatment option for various conditions associated with neuropathic pain and tissue damage

Product Name	A*R*A*-2*9*0
Active Ingredient	A*R*A*-2*9*0
Dosage Form	Injection
Strength	5mg/vial
Packaging	10vials/Box     Customizable version
Manufacturer	Sinopharmatech Co., Ltd.

 

    Storage Conditions
      • Store in a refrigerated environment at 2°C-8°C, away from light
      • Short-term transportation is possible at 15°C-25°C but should not exceed seven days
      • Inspect the solution before use to ensure it is clear and free from particles or discoloration
 

Support different package method

For more information, please feel free to contact us.

Why Choose Us?

High Purity (≥98%)

Flexible Dosing Options

GMP-Certified Quality

Weekly Dosing for Convenience